The 2024 revised edition of the Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock (J-SSCG 2024) is published by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine. This is the fourth revision since the first edition was published in 2012. The purpose of the guidelines is to assist healthcare providers in making appropriate decisions in the treatment of sepsis and septic shock, leading to improved patient outcomes. We aimed to create guidelines that are easy to understand and use for physicians who recognize sepsis and provide initial management, specialized physicians who take over the treatment, and multidisciplinary healthcare providers, including nurses, physical therapists, clinical engineers, and pharmacists. The J-SSCG 2024 covers the following nine areas: diagnosis of sepsis and source control, antimicrobial therapy, initial resuscitation, blood purification, disseminated intravascular coagulation, adjunctive therapy, post-intensive care syndrome, patient and family care, and pediatrics. In these areas, we extracted 78 important clinical issues. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) method was adopted for making recommendations, and the modified Delphi method was used to determine recommendations by voting from all committee members. As a result, 42 GRADE-based recommendations, 7 good practice statements, and 22 information-to-background questions were created as responses to clinical questions. We also described 12 future research questions.

日本重症医学会和日本急性医学协会发布了2024年修订版《日本脓毒症及脓毒性休克管理临床实践指南》（J-SSCG 2024）。这是自2012年第一版出版以来的第四次修订。该指南的目的是帮助医疗保健提供者在脓毒症和脓毒性休克的治疗中做出适当的决定，从而改善患者的预后。我们的目标是为识别脓毒症并提供初始管理的医生、接管治疗的专业医生以及包括护士、物理治疗师、临床工程师和药剂师在内的多学科医疗保健提供者创建易于理解和使用的指南。J-SSCG 2024涵盖以下九个领域：败血症诊断和源头控制、抗菌治疗、初始复苏、血液净化、弥散性血管内凝血、辅助治疗、重症监护后综合征、患者和家庭护理以及儿科。在这些领域，我们提取了78个重要的临床问题。采用GRADE（Grading of Recommendations Assessment，Development and Evaluation）法提出建议，采用改进的德尔菲法由委员会全体成员投票确定建议。结果，42个基于grade的建议，7个良好实践声明和22个信息背景问题被创建作为对临床问题的回应。我们还描述了12个未来的研究问题。